Treatment of Hypertensive and Hypercholesterolaemic Patients with the Triple Fixed Combination of Atorvastatin, Perindopril and Amlodipine: The Results of the CORAL Study
AbstractIntroductionHypertension and hypercholesterolaemia are important contributors to the development and progression of atherosclerosis. The coexistence of these two conditions is rather common: hypercholesterolaemia is present in 40 –60% of hypertensive patients. Remarkably, patient compliance with antihypertensive regimens is better than with statin therapy. Thus, the inclusion of statins and blood pressure-lowering agents into a fixed combination might even double the effectiveness of statin therapy, and thereby achieve sig nificantly greater reduction of cardiovascular risk. The CORAL study was a 3-month, prospective, multicentre, observational, non-interventional survey, which evaluated the blood pressure- and lipid-lowering efficacy of the triple fixed combination of atorvastatin/perindopril/amlodipine, administered in various dose combinations.MethodsThe efficacy of the triple fixed combination was reflected by the changes of the blood pressure readings taken in the office and during 24-h blood pressure monitoring (3 months elapsed between visits 1 and 3). The laboratory parameters obtained during data acquisition were also recorded.ResultsAfter 3 months of therapy, mean office blood pressure decreased from 158.5 ± 16.7/91.7 ± 9.4 to 132.2 ± 8.3/80.1 ± 6.8 mmHg (p
Publication date: August 2019Source: Nutrition, Metabolism and Cardiovascular Diseases, Volume 29, Issue 8Author(s): Marialaura Bonaccio, Augusto Di Castelnuovo, Simona Costanzo, Mariarosaria Persichillo, Amalia De Curtis, Chiara Cerletti, Maria Benedetta Donati, Giovanni De Gaetano, Licia Iacoviello
Publication date: Available online 19 July 2019Source: Pharmacological ResearchAuthor(s): Chiara Pavanello, Andrea Baragetti, Adriana Branchi, Liliana Grigore, Samuela Castelnuovo, Eleonora Giorgio, Alberico L. Catapano, Laura Calabresi, Monica GomaraschiAbstractLysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesteryl esters (CE) and triglycerides (TG) within the lysosomes; generated cholesterol and free fatty acids (FFA) are released in the cytosol where they can regulate their own synthesis and metabolism. When LAL is not active, as in case of genetic mutations, CE and TG accumulate in the lysosomal c...
Introduction: Statins are prescribed for patients with cardiovascular disease (CVD), along with the recommendation of adopting healthy diets. This stufy aimed to evaluate the independent and the combined effect of statins and Mediterranean diet (MD) towards mortality risk in subjects with previous CVD by using real-life data from a population-based prospective cohort. We performed a longitudinal analysis on 1,180 subjects (mean age 67.7 ± 10) with prior CVD at enrollment in the Moli-sani study and followed up for 7.9 years (median).
This study investigated the effects of statin in AF patients who experienced acute ischemic stroke.MethodsData from patients with AF experiencing first-ever ischemic stroke between 2001 and 2010 were collected from the Taiwan National Health Insurance Research Database and categorized into non-statin and statin groups. The statin group was further divided into pre-stroke statin (those who began statin therapy before stroke) and post-stroke statin (those who began statin therapy after stroke) groups. The risks for recurrent ischemic stroke, coronary artery disease (CAD), intracranial hemorrhage (ICH), and 1-year mortality w...
Conclusion The prevalence of statin induced new onset of diabetes is 7.03%. The main risk factors identified in the study were in older patients (≥60 years), rosuvastatin therapy, high dose and longer duration of statin therapy. PMID: 31311373 [PubMed - as supplied by publisher]
Here ’s the new list of what your health insurance plan might cover next year under Trump Treasury’s broadened definition of preventative care services.
Conclusion: Statin can be used as an adjuvant to erythropoietin in management of anemia in patients of chronic kidney disease, who show hyporesponsiveness to increased doses of erythropoietin, by its anti-inflammatory properties. PMID: 31313547 [PubMed - in process]
Authors: Iyengar SS, Bansal M, Sawhney J, Wander G, Narasingan SN, Chandra KS, D P, Nair T, Krishnakumar B, Deshpande N, Bardoloi N, Shetty S, Desai N, Pancholia AK, Swamy A Abstract The burden of atherosclerotic cardiovascular (CV) disease is alarmingly high and increasing in our country. Dyslipidemia is one of the major modifiable risk factors, and INTERHEART study showed that dyslipidemia had the highest population attributable risk for myocardial infarction. In the management of dyslipidemia, low-density lipoprotein cholesterol (LDL-C) is the primary therapeutic target. In addition to therapeutic lifestyle chan...
ConclusionsMultiple doses of DS-8500a increased exposure to rosuvastatin and atorvastatin. This short-term study suggests that the impact of DS-8500a coadministration on atorvastatin exposure is limited and may not be clinically relevant. Nevertheless, caution may be necessary when patients are coadministered rosuvastatin with DS-8500a.ClinicalTrials.gov identifierNCT03699774.Japan Pharmaceutical Information Center identifierJapicCTI-152878.
Nearly half of preventable patient harm was accounted for by drug-related incidents and other treatments Related items fromOnMedica MHRA tightens licence restrictions on valproate for women NI launches ‘One Health’ plan to tackle antimicrobial resistance Antibiotic scrip rates lower in CAM-trained practices GPs defend practice on prescribing statins NHS England in bid to cut drugs waste